{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:21:09Z","timestamp":1790767269671,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,7,27]],"date-time":"2012-07-27T00:00:00Z","timestamp":1343347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s11864-012-0206-4","type":"journal-article","created":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T05:53:56Z","timestamp":1343282036000},"page":"491-504","source":"Crossref","is-referenced-by-count":27,"title":["Treatment of Leptomeningeal Spread of NSCLC: A Continuing Challenge"],"prefix":"10.1007","volume":"13","author":[{"given":"Seema","family":"Nagpal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Riess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,7,27]]},"reference":[{"key":"206_CR1","unstructured":"Cancer Facts and Figures 2012. Available at http:\/\/www.cancer.org\/acs\/groups\/content\/@epidemiologysurveilance\/documents\/document\/acspc-031941.pdf . Accessed 29 May 2012."},{"issue":"Suppl(May 20)","key":"206_CR2","first-page":"7542","volume":"5","author":"AF Eichler","year":"2012","unstructured":"Eichler AF, Wang DL, Joshi VA, et al. EGFR mutation status and survival after diagnosis of brain metastasis in non-small cell lung cancer. J Clin Oncol. 2012;5(Suppl(May 20)):7542.","journal-title":"J Clin Oncol"},{"issue":"8","key":"206_CR3","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/cncr.22565","volume":"109","author":"AM Chen","year":"2007","unstructured":"Chen AM, Jahan TM, Jablons DM, et al. Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain. Cancer. 2007;109(8):1668\u201375.","journal-title":"Cancer"},{"issue":"11","key":"206_CR4","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00432-010-0831-x","volume":"136","author":"K Oechsle","year":"2010","unstructured":"Oechsle K, Lange-Brock V, Kruell A, et al. Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis. J Cancer Res Clin Oncol. 2010;136(11):1729\u201335.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"206_CR5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0733-8619(02)00032-4","volume":"21","author":"S Kesari","year":"2003","unstructured":"Kesari S, Batchelor TT. Leptomeningeal metastases. Neurol Clin. 2003;21(1):25\u201366.","journal-title":"Neurol Clin"},{"issue":"5","key":"206_CR6","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ejrad.2011.02.020","volume":"81","author":"S Pauls","year":"2012","unstructured":"Pauls S, Fischer AC, Brambs HJ, et al. Use of magnetic resonance imaging to detect neoplastic meningitis: limited use in leukemia and lymphoma but convincing results in solid tumors. Eur J Radiol. 2012;81(5):974\u20138.","journal-title":"Eur J Radiol"},{"key":"206_CR7","doi-asserted-by":"crossref","unstructured":"Strik H, Proemmel P, Pilgram-Pastor S, Buhk JH. Neoplastic Meningitis- is MRI as sensitive as CSF cytology? J Clin Oncol. 2009;25(15 supplement).","DOI":"10.1200\/jco.2009.27.15_suppl.9566"},{"issue":"4","key":"206_CR8","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/(SICI)1097-0142(19980215)82:4<733::AID-CNCR17>3.0.CO;2-Z","volume":"82","author":"MJ Glantz","year":"1998","unstructured":"Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer. 1998;82(4):733\u20139.","journal-title":"Cancer"},{"issue":"10","key":"206_CR9","doi-asserted-by":"crossref","first-page":"752","DOI":"10.18632\/oncotarget.336","volume":"2","author":"AS Patel","year":"2011","unstructured":"Patel AS, Allen JE, Dicker DT, et al. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget. 2011;2(10):752\u201360.","journal-title":"Oncotarget"},{"issue":"3","key":"206_CR10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2010.29.1609","volume":"29","author":"EM Gore","year":"2011","unstructured":"Gore EM, Bae K, Wong SJ, et al. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol. 2011;29(3):272\u20138.","journal-title":"J Clin Oncol"},{"key":"206_CR11","doi-asserted-by":"crossref","unstructured":"Patel N, Lester JF, Coles B, Macbeth FR. Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small cell lung cancer. Cochrane Database Syst Rev. 2009;18(2):CD005221. doi: 10.1002\/14651858.CD005221 .","DOI":"10.1002\/14651858.CD005221"},{"issue":"31","key":"206_CR12","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.1200\/JCO.2007.12.5468","volume":"25","author":"C Pottgen","year":"2007","unstructured":"Pottgen C, Eberhardt W, Grannass A, et al. Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. J Clin Oncol. 2007;25(31):4987\u201392.","journal-title":"J Clin Oncol"},{"issue":"2","key":"206_CR13","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/JTO.0b013e3182398e4f","volume":"7","author":"PG Morris","year":"2012","unstructured":"Morris PG, Reiner AS, Szenberg OR, et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol. 2012;7(2):382\u20135.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"206_CR14","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1985.3.4.485","volume":"3","author":"FM Balis","year":"1985","unstructured":"Balis FM, Savitch JL, Bleyer WA, Reaman GH, Poplack DG. Remission induction of meningeal leukemia with high-dose intravenous methotrexate. J Clin Oncol. 1985;3(4):485\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"206_CR15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF02228887","volume":"3","author":"JA Lopez","year":"1985","unstructured":"Lopez JA, Nassif E, Vannicola P, et al. Central nervous system pharmacokinetics of high-dose cytosine arabinoside. J Neurooncol. 1985;3(2):119\u201324.","journal-title":"J Neurooncol"},{"issue":"4","key":"206_CR16","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1200\/JCO.1998.16.4.1561","volume":"16","author":"MJ Glantz","year":"1998","unstructured":"Glantz MJ, Cole BF, Recht L, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol. 1998;16(4):1561\u20137.","journal-title":"J Clin Oncol"},{"issue":"3","key":"206_CR17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.lungcan.2011.11.022","volume":"76","author":"JH Park","year":"2012","unstructured":"Park JH, Kim YJ, Lee JO, et al. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer. 2012;76(3):387\u201392.","journal-title":"Lung Cancer"},{"issue":"2","key":"206_CR18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11060-010-0128-6","volume":"99","author":"JL Clarke","year":"2010","unstructured":"Clarke JL, Pao W, Wu N, et al. High-dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol. 2010;99(2):283\u20136.","journal-title":"J Neurooncol"},{"issue":"12","key":"206_CR19","first-page":"1364","volume":"13","author":"C Grommes","year":"2011","unstructured":"Grommes C, Oxnard GR, Kris MG, et al. \"Pulsatile\" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neurooncol. 2011;13(12):1364\u20139.","journal-title":"Neurooncol"},{"issue":"6","key":"206_CR20","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00280-011-1555-6","volume":"67","author":"T Masuda","year":"2011","unstructured":"Masuda T, Hattori N, Hamada A, et al. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother Pharmacol. 2011;67(6):1465\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"206_CR21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/jpet.110.167601","volume":"334","author":"S Agarwal","year":"2010","unstructured":"Agarwal S, Sane R, Gallardo JL, et al. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther. 2010;334(1):147\u201355.","journal-title":"J Pharmacol Exp Ther"},{"issue":"15","key":"206_CR22","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1200\/JCO.2010.34.1313","volume":"29","author":"DB Costa","year":"2011","unstructured":"Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29(15):e443\u2013445.","journal-title":"J Clin Oncol"},{"key":"206_CR23","doi-asserted-by":"crossref","unstructured":"Weickhardt AJ, Burke JM, Gan G, et al. Continuation of EGFR\/ALK inhibition after local therapy of oligoprogressive disease in EGFR mutant (Mt) and ALK + non-small cell lung cancer (NSCLC). J Clin Oncol. 2012;30(suppl; abstr 7526).","DOI":"10.1200\/jco.2012.30.15_suppl.7526"},{"issue":"4","key":"206_CR24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00280-006-0285-7","volume":"59","author":"SL Stapleton","year":"2007","unstructured":"Stapleton SL, Reid JM, Thompson PA, et al. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. Cancer Chemother Pharmacol. 2007;59(4):461\u20136.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"206_CR25","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1093\/annonc\/mdr003","volume":"22","author":"F Barlesi","year":"2011","unstructured":"Barlesi F, Gervais R, Lena H, et al. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07\u201301). Ann Oncol. 2011;22(11):2466\u201370.","journal-title":"Ann Oncol"},{"issue":"2","key":"206_CR26","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.lungcan.2009.06.018","volume":"68","author":"A Bearz","year":"2010","unstructured":"Bearz A, Garassino I, Tiseo M, et al. Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. Lung Cancer. 2010;68(2):264\u20138.","journal-title":"Lung Cancer"},{"issue":"12","key":"206_CR27","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1002\/1097-0142(19950615)75:12<2919::AID-CNCR2820751220>3.0.CO;2-9","volume":"75","author":"MJ Glantz","year":"1995","unstructured":"Glantz MJ, Hall WA, Cole BF, et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer. 1995;75(12):2919\u201331.","journal-title":"Cancer"},{"key":"206_CR28","first-page":"115","volume-title":"Clinical studies in the central nervous system pharmacology of methotrexate. Clinical Pharmacology of Anti-neoplastic Drugs","author":"WA Bleyer","year":"1978","unstructured":"Bleyer WA. Clinical studies in the central nervous system pharmacology of methotrexate. Clinical Pharmacology of Anti-neoplastic Drugs. Amsterdam: Elsevier\/North-Holland Biomedical; 1978. p. 115\u201331."},{"issue":"4","key":"206_CR29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM197507242930402","volume":"293","author":"WR Shapiro","year":"1975","unstructured":"Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293(4):161\u20136.","journal-title":"N Engl J Med"},{"issue":"5","key":"206_CR30","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.V51.5.835.835","volume":"51","author":"WA Bleyer","year":"1978","unstructured":"Bleyer WA, Poplack DG, Simon RM. \"Concentration x time\" methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood. 1978;51(5):835\u201342.","journal-title":"Blood"},{"issue":"9","key":"206_CR31","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/1097-0142(19821101)50:9<1676::AID-CNCR2820500903>3.0.CO;2-S","volume":"50","author":"LJ Ettinger","year":"1982","unstructured":"Ettinger LJ, Chervinsky DS, Freeman AI, et al. Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin's lymphoma. Cancer. 1982;50(9):1676\u201382.","journal-title":"Cancer"},{"issue":"2","key":"206_CR32","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<511::AID-CNCR33>3.0.CO;2-H","volume":"85","author":"AM Moser","year":"1999","unstructured":"Moser AM, Adamson PC, Gillespie AJ, et al. Intraventricular concentration times time (C x T) methotrexate and cytarabine for patients with recurrent meningeal leukemia and lymphoma. Cancer. 1999;85(2):511\u20136.","journal-title":"Cancer"},{"issue":"2","key":"206_CR33","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1215\/15228517-2007-059","volume":"10","author":"MD Groves","year":"2008","unstructured":"Groves MD, Glantz MJ, Chamberlain MC, et al. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol. 2008;10(2):208\u201315.","journal-title":"Neuro Oncol"},{"issue":"11","key":"206_CR34","first-page":"3394","volume":"5","author":"MJ Glantz","year":"1999","unstructured":"Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5(11):3394\u2013402.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"206_CR35","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/cncr.24921","volume":"116","author":"MJ Glantz","year":"2010","unstructured":"Glantz MJ, Van Horn A, Fisher R, et al. Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer. 2010;116(8):1947\u201352.","journal-title":"Cancer"},{"issue":"4","key":"206_CR36","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1532\/IJH97.06205","volume":"85","author":"Y Matsumoto","year":"2007","unstructured":"Matsumoto Y, Horiike S, Fujimoto Y, et al. Effectiveness and limitation of gamma knife radiosurgery for relapsed central nervous system lymphoma: a retrospective analysis in one institution. Int J Hematol. 2007;85(4):333\u20137.","journal-title":"Int J Hematol"},{"issue":"25","key":"206_CR37","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2009.26.7278","volume":"28","author":"TA Yap","year":"2010","unstructured":"Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010;28(25):3965\u201372.","journal-title":"J Clin Oncol"},{"issue":"suppl; abstr 75","key":"206_CR38","doi-asserted-by":"crossref","first-page":"7525","DOI":"10.1200\/jco.2011.29.15_suppl.7525","volume":"29","author":"YY Janjigian","year":"2011","unstructured":"Janjigian YY, Groen HJ, Horn L, Smit EF, et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. Am Soc Clin Oncol Meet. 2011;29(suppl; abstr 7525):7525.","journal-title":"Am Soc Clin Oncol Meet"},{"issue":"2","key":"206_CR39","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00280-010-1522-7","volume":"68","author":"JM Sun","year":"2011","unstructured":"Sun JM, Nam MH, Chung JY, et al. Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats. Cancer Chemother Pharmacol. 2011;68(2):531\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"206_CR40","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/B:NEON.0000003752.89814.ca","volume":"65","author":"P Giglio","year":"2003","unstructured":"Giglio P, Tremont-Lukats IW, Groves MD. Response of neoplastic meningitis from solid tumors to oral capecitabine. J Neurooncol. 2003;65(2):167\u201372.","journal-title":"J Neurooncol"},{"issue":"1","key":"206_CR41","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejim.2008.04.015","volume":"20","author":"S Paydas","year":"2009","unstructured":"Paydas S, Bicakci K, Yavuz S. Dramatic response with capecitabine after cranial radiation to the brain parenchymal and leptomeningeal metastases from lung cancer. Eur J Intern Med. 2009;20(1):96\u20139.","journal-title":"Eur J Intern Med"},{"issue":"7","key":"206_CR42","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1200\/JCO.2005.06.053","volume":"23","author":"SM Blaney","year":"2005","unstructured":"Blaney SM, Balis FM, Berg S, et al. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol. 2005;23(7):1555\u201363.","journal-title":"J Clin Oncol"},{"issue":"7","key":"206_CR43","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1212\/01.wnl.0000178981.39984.c2","volume":"65","author":"JC Reijneveld","year":"2005","unstructured":"Reijneveld JC, Brandsma D, Boogerd W, et al. CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. Neurology. 2005;65(7):1120\u20132.","journal-title":"Neurology"},{"issue":"5","key":"206_CR44","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.ijrobp.2009.12.061","volume":"79","author":"VA Levin","year":"2011","unstructured":"Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2011;79(5):1487\u201395.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-012-0206-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-012-0206-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-012-0206-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T01:47:35Z","timestamp":1642902455000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-012-0206-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,27]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["206"],"URL":"https:\/\/doi.org\/10.1007\/s11864-012-0206-4","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,27]]}}}